There are currently 941 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University health system. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
All
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: M3-Emerging Medical Resarch, Durham, North Carolina
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
NCT04669548
Recruiting
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/26/2022
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury, Cardiovascular Surgery
Register for Updates
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
NCT04893486
Recruiting
A Phase 2b study looks at the safety and efficacy of a treatment that is being investigated for people with certain diseases. This study will be conducted at multiple centers in the United States where participants with Gorlin Syndrome, also known as basal cell nevus syndrome, will be randomly placed into two groups; one group will receive the active topical gel, the other a topical vehicle gel, also know as placebo. Participants will apply this topical product to their face once a day for 6 mon... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/26/2022
Locations: Duke University, Durham, North Carolina
Conditions: BCCs in Gorlin Syndrome Patients
Register for Updates
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
NCT01745237
Recruiting
The primary objective of this study was to determine the ability of cardiac magnetic resonance (CMR) to identify cardiac involvement in patients with sarcoidosis. Patients were to undergo CMR in addition to routine clinical evaluation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/29/2022
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Sarcoidosis
Register for Updates
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Duke Cancer Institute (Adults only), Durham, North Carolina
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Struvite Stones Antibiotic Study
NCT02375295
Recruiting
The aim of this research is to determine an effective antibiotic regimen following definitive surgical therapy of kidney stones caused by bacterial infection (struvite stones).
Gender:
All
Ages:
19 years and above
Trial Updated:
05/16/2022
Locations: Duke University, Durham, North Carolina
Conditions: Kidney Stones
Register for Updates
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
NCT03309111
Recruiting
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2022
Locations: Duke Clinical Research Institute, Durham, North Carolina
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
NCT03540771
Recruiting
This is a comparative effectiveness study of two pragmatic models aiming to introduce palliative care for end stage liver disease patients. The 2 comparators are: Model 1: Consultative Palliative Care (i.e. direct access to Palliative Care provider), Model 2: Trained Hepatologist- led PC intervention (i.e. a hepatologist will receive formal training to deliver Palliative Care services) Primary Outcome: The change in quality of life from baseline to 3 months post enrollment as assessed by FACT-... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/05/2022
Locations: Durham V.A. Medical Center, Durham, North Carolina
Conditions: End Stage Liver Disease
Register for Updates
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
NCT01957722
Recruiting
This study is to compare NOVOCART 3D relative to Microfracture for the treatment of knee cartilage defects. Efficacy will be evaluated by both pain and function. Safety will also be evaluated.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/01/2022
Locations: Duke University, Durham, North Carolina
Conditions: Articular Cartilage of the Femoral Condyle Between 2-6cm2
Register for Updates
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Recruiting
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute-Testing Site, Durham, North Carolina
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Duke Cancer Center, Duke University Medical Center, Durham, North Carolina
Conditions: Solid Tumors, GI Cancer
Register for Updates
Longitudinal Performance of Epi proColon
NCT03218423
Recruiting
This study will evaluate longitudinal performance of Epi proColon with respect to test positivity, longitudinal adherence to Epi proColon screening, adherence to follow-up colonoscopy and diagnostic yield, as well as assay failure rates.
Gender:
All
Ages:
Between 50 years and 74 years
Trial Updated:
10/29/2021
Locations: Duke University, Durham, North Carolina
Conditions: Colorectal Cancer, Colorectal Neoplasms
Register for Updates